Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Summit Therapeutics Inc. SMMT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$26.00
+24.7%

Summit Therapeutics Inc. (SMMT) is a Biotechnology company in the Healthcare sector, currently trading at $20.85. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SMMT = $26 (+24.7% upside).

Valuation: SMMT trades at a trailing Price-to-Earnings (P/E) of -13.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 43.17.

Net income is $1.1B (loss), growing at -334.8%/yr. Net profit margin is 0% (thin). Gross margin is -257% (+0 pp trend).

Balance sheet: total debt is $21M against $659M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 9.87 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $751M.

Analyst outlook: 15 / 20 analysts rate SMMT as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 53/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 29/100 (Fail), Future 79/100 (Pass), Income ?/100 (Fail).

$26.00
▲ 24.7% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Summit Therapeutics Inc., the average price target is $26.00, with a high forecast of $40.00, and a low forecast of $16.00.
Highest Price Target
$40.00
Average Price Target
$26.00
Lowest Price Target
$16.00

SMMT SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 53/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 29/100
Gross margin is + market cap
FUTURE 79/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SMMT

~
VALUE Partial
53/100
SMMT trades at a trailing Price-to-Earnings (P/E) of -13.4 (S&P 500 average ~25). Forward PEG 43.17 — overvalued. Trailing PEG 0.79. Analyst consensus target is $26, implying +24.7% from the current price $21. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
SMMT: -100%/yr revenue is, -334.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SMMT: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 9.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
29/100
SMMT: Gross margin is -257% (+0 pp trend), $16B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 29/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
79/100
Analyst outlook: 15 / 20 analysts rate SMMT as buy (75%). Analyst consensus target is $26 (+24.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range13.83-36.91
Volume2.32M
Avg Volume (30D)2.54M
Market Cap$15.52B
Beta (1Y)-1.37
Share Statistics
EPS (TTM)-1.44
Shares Outstanding$747.7M
IPO Date2015-03-05
Employees159
CEORobert W. Duggan
Financial Highlights & Ratios
Gross Profit$-108.36K
EBITDA$-801.12M
Net Income$-1.08B
Operating Income$-1.09B
Total Cash$713.45M
Total Debt$20.89M
Net Debt$-204.38M
Total Assets$751.18M
Price / Earnings (P/E)-14.5
Analyst Forecast
1Y Price Target$24.00
Target High$40.00
Target Low$16.00
Upside+15.1%
Rating ConsensusBuy
Analysts Covering20
Buy 75% Hold 25% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS86627T1088

Price Chart

Track all markets on TradingView
SMMT
Summit Therapeutics Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
13.83 52WK RANGE 36.91

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 NKTX
NKTX
Nkarta, Inc.
$2.29
-0.22%
 KZR
KZR
Kezar Life Sciences, Inc.
$7.36
-0.94%
 KRON
KRON
Kronos Bio, Inc.
$0.88
+1.49%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message